Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Optimer Pharmaceuticals
So what: The drug is meant to treat clostridium difficile-associated diarrhea, or CDAD. Patients being treated with the drug showed speedier resolution of diarrhea and lower risk of death during the first 12 days after treatment compared to patients treated with Vancomycin.
Now what: The primary author of the analysis, Dr. Sarah Walker, said, "We were encouraged by the results of the phase 3 clinical studies and believed that a more comprehensive look at the patient characteristics of the phase 3 study participants might yield even greater insights into the use of DIFICID for the treatment of CDAD." Canaccord Genuity, which rates the stock a "Buy," followed up with some positive comments that additional upside may come from increased uptake among doctors. The company has a $20 price target on Optimer shares, which would represent a 38% to today's close.
Interested in more info on Optimer Pharmaceuticals? Add it to your watchlist.
Fool contributor Evan Niu holds no position in any company mentioned. Check out his holdings and a short bio. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.